Preventive treatment of headache with slow-release dihydroergotamine: Comparison of dosage protocols

G. A. Buscaino, F. Sorge, G. Bussone, F. Frediani, M. Giacovazzo, P. Martelletti, G. C. Manzoni, N. Martucci, G. Nappi, G. Micieli, F. M. Puca, S. Genco, T. Sacquegna, G. Dalla Volta

Research output: Contribution to journalArticle

Abstract

Ninety patients (63 women and 27 men; mean age, 37 years) suffering from common migraine were treated, according to a double-blind experimental scheme, with a new formulation of slow-release dihydroergotamine (DHE-CP) either 5 mg BID or 10 once daily for two months. The results show the preventive treatment to be effective, with a significant reduction (P <0.01 between times) in the severity and frequency of headache and the associated symptoms, independent of the dosage scheme. Tolerance was also considered to be good in that only 4% of the patients (three patients receiving DHE-CP BID and one patient once daily) had to discontinue treatment due to side effects. The daily dosage of DHE-CP may be administered either in a single dose or twice a day with comparable therapeutic effectiveness and safety.

Original languageEnglish
Pages (from-to)925-935
Number of pages11
JournalCurrent Therapeutic Research
Volume49
Issue number6
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Preventive treatment of headache with slow-release dihydroergotamine: Comparison of dosage protocols'. Together they form a unique fingerprint.

  • Cite this

    Buscaino, G. A., Sorge, F., Bussone, G., Frediani, F., Giacovazzo, M., Martelletti, P., Manzoni, G. C., Martucci, N., Nappi, G., Micieli, G., Puca, F. M., Genco, S., Sacquegna, T., & Dalla Volta, G. (1991). Preventive treatment of headache with slow-release dihydroergotamine: Comparison of dosage protocols. Current Therapeutic Research, 49(6), 925-935.